Warm Autoimmune Hemolytic Anemia Waiha Market

DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (wAIHA)–Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of the Warm Autoimmune Hemolytic Anemia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Warm Autoimmune Hemolytic Anemia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Warm Autoimmune Hemolytic Anemia symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Warm Autoimmune Hemolytic Anemia symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Warm Autoimmune Hemolytic Anemia (wAIHA) Disease Understanding and Treatment Algorithm

Warm Autoimmune Hemolytic Anemia (wAIHA) Overview

Warm Autoimmune Hemolytic Anemia (wAIHA) is one of the most prevalent psychiatric disorders and has been projected by the World Health Organisation to be the leading cause of disease burden in high-income countries by 2032. Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation. Autoantibodies are produced by both tissue and circulating self-reactive B lymphocytes, following cooperation with T helper lymphocytes.

 

Warm Autoimmune Hemolytic Anemia is the most common type of autoimmune hemolytic anemia, comprising ∼70–80% of all adult cases and ∼50% of the pediatric cases. More than half of these cases are called primary due to undefined etiology, while the rest is termed as secondary to lymphoproliferative syndromes, malignant diseases including chronic lymphoblastic leukemia (CLL), non-Hodgkin’s lymphoma, and solid tumors.

 

Currently, there are no approved therapies for the management of Warm Autoimmune Hemolytic Anemia, with only one-third of the patients maintaining sustained disease control once steroids are discontinued.

 

As per DelveInsight’s estimation, the future of Warm Autoimmune Hemolytic Anemia treatment is continuing to trend toward complement inhibitors, Syk kinase inhibitors, and FcRn receptor antagonist MAb. If these therapies are ultimately successfully commercialized, they have the potential to transform the current standard of care for Warm Autoimmune Hemolytic Anemia patients.

 

Warm Autoimmune Hemolytic Anemia (wAIHA) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Warm Autoimmune Hemolytic Anemia (wAIHA) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Warm Autoimmune Hemolytic Anemia (wAIHA) market report gives a thorough understanding of Warm Autoimmune Hemolytic Anemia (wAIHA) symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Warm Autoimmune Hemolytic Anemia (wAIHA) treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology

The epidemiology division’s Warm Autoimmune Hemolytic Anemia (wAIHA) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Warm Autoimmune Hemolytic Anemia epidemiology segmented as the Total Prevalent Cases of Autoimmune Hemolytic Anemia, Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia, Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia, and Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia. The report includes the Prevalent Warm Autoimmune Hemolytic Anemia scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise-Warm Autoimmune Hemolytic Anemia Epidemiology

The epidemiology segment also provides the Warm Autoimmune Hemolytic Anemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 7MM Prevalent cases of Warm Autoimmune Hemolytic Anemia were 115,641 cases in 2020.

Warm Autoimmune Hemolytic Anemia (wAIHA) Drug Chapters

The drug chapter segment of the Warm Autoimmune Hemolytic Anemia (wAIHA) report encloses the detailed analysis of Warm Autoimmune Hemolytic Anemia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Warm Autoimmune Hemolytic Anemia (wAIHA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Warm Autoimmune Hemolytic Anemia (wAIHA) Emerging Drugs

 

Fostamatinib (Rigel Pharmaceuticals)

Fostamatinib (R935788) is a small molecule Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities is being developed by Rigel Pharmaceuticals. It inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses, and tissue damage.

 

Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). The major metabolite of fostamatinib, R406, inhibits signal transduction of Fc-activating receptors and B-cell receptor. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets

Products detail in the report…

Warm Autoimmune Hemolytic Anemia Market Outlook

The Warm Autoimmune Hemolytic Anemia (wAIHA) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Warm Autoimmune Hemolytic Anemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of Warm Autoimmune Hemolytic Anemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, Warm Autoimmune Hemolytic Anemia (wAIHA) market in 7MM is expected to change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Warm Autoimmune Hemolytic Anemia market in 7MM. The market size of Warm Autoimmune Hemolytic Anemia in the seven major markets was found to be USD 545 million in 2022.

 

The United States Market Outlook

This section provides a total of Warm Autoimmune Hemolytic Anemia market size and market size by therapies in the United States.

 

The United States accounts for higher Warm Autoimmune Hemolytic Anemia market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total Warm Autoimmune Hemolytic Anemia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Warm Autoimmune Hemolytic Anemia market size and market size by therapies in Japan are also mentioned.

Warm Autoimmune Hemolytic Anemia (wAIHA) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Warm Autoimmune Hemolytic Anemia market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Warm Autoimmune Hemolytic Anemia (wAIHA) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Warm Autoimmune Hemolytic Anemia (wAIHA) key players involved in developing targeted therapeutics.

 

Major players Fostamatinib (Rigel Pharmaceuticals), Apellis’ APL-2 and others are being assessed as potential therapies to be available in the market in the coming future.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Warm Autoimmune Hemolytic Anemia emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working on Warm Autoimmune Hemolytic Anemia domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Warm Autoimmune Hemolytic Anemia market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Warm Autoimmune Hemolytic Anemia Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Warm Autoimmune Hemolytic Anemia explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Warm Autoimmune Hemolytic Anemia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Warm Autoimmune Hemolytic Anemia provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Warm Autoimmune Hemolytic Anemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Warm Autoimmune Hemolytic Anemia market

Report Highlights

  • In the coming years, Warm Autoimmune Hemolytic Anemia market is set to change due to the rising awareness of the disease, resistant to the current antibiotic regime, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Warm Autoimmune Hemolytic Anemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Warm Autoimmune Hemolytic Anemia. The launch of emerging therapies will significantly impact the Community Acquired Bacterial Pneumonia  market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Warm Autoimmune Hemolytic Anemia
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Warm Autoimmune Hemolytic Anemia (wAIHA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Warm Autoimmune Hemolytic Anemia (wAIHA) Pipeline Analysis
  • Warm Autoimmune Hemolytic Anemia (wAIHA) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Warm Autoimmune Hemolytic Anemia (wAIHA) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Warm Autoimmune Hemolytic Anemia (wAIHA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Warm Autoimmune Hemolytic Anemia (wAIHA) Market share (%) distribution in 2022, and how would it look in 2032?
  • What would be the Warm Autoimmune Hemolytic Anemia (wAIHA) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2032)?
  • What are the market’s key findings across 7MM, and which country will have the largest Warm Autoimmune Hemolytic Anemia (wAIHA) market Size during the forecast period (2021–2032)?
  • At what CAGR, the Warm Autoimmune Hemolytic Anemia (wAIHA) market is expected to grow by 7MM during the forecast period (2021–2032)?
  • What would be the Warm Autoimmune Hemolytic Anemia (wAIHA) market outlook across the 7MM during the forecast period (2021–2032)?
  • What would be the Warm Autoimmune Hemolytic Anemia (wAIHA) market growth till 2030, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Warm Autoimmune Hemolytic Anemia (wAIHA)?
  • What is the historical Warm Autoimmune Hemolytic Anemia (wAIHA) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Warm Autoimmune Hemolytic Anemia (wAIHA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Warm Autoimmune Hemolytic Anemia (wAIHA)?
  • Out of all 7MM countries, which country would have the highest Prevalent Warm Autoimmune Hemolytic Anemia (wAIHA) population during the forecast period (2021–2032)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Warm Autoimmune Hemolytic Anemia (wAIHA)?
  • What are the current treatment guidelines for treating Warm Autoimmune Hemolytic Anemia (wAIHA) in the USA, Europe, and Japan?
  • What are the Warm Autoimmune Hemolytic Anemia (wAIHA) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Warm Autoimmune Hemolytic Anemia (wAIHA)?
  • How many therapies are developed by each company for the treatment of Warm Autoimmune Hemolytic Anemia (wAIHA)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Warm Autoimmune Hemolytic Anemia (wAIHA)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Warm Autoimmune Hemolytic Anemia (wAIHA) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Warm Autoimmune Hemolytic Anemia (wAIHA) and their status?
  • What are the key designations that have been granted for the emerging therapies for Warm Autoimmune Hemolytic Anemia (wAIHA)?
  • What are the global historical and forecasted markets of Warm Autoimmune Hemolytic Anemia (wAIHA)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Warm Autoimmune Hemolytic Anemia (wAIHA) market
  • To understand the future market competition in the Warm Autoimmune Hemolytic Anemia (wAIHA) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Warm Autoimmune Hemolytic Anemia (wAIHA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Warm Autoimmune Hemolytic Anemia (wAIHA) market
  • To understand the future market competition in the Warm Autoimmune Hemolytic Anemia (wAIHA) market

1. Key Insights

2. Report Introduction

3. wAIHA Market Overview at a Glance

3.1. Market Share (%) Distribution of wAIHA in 2019

3.2. Market Share (%) Distribution of wAIHA in 2032

4. Executive Summary of Warm Autoimmune Hemolytic Anemia

5. Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification

5.4. Causes

5.5. Pathophysiology

5.6. Clinical Manifestation

5.7. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Warm Autoimmune Hemolytic Anemia

6.3. Assumption and Rationale: 7MM

6.4. The United States

6.4.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in the US

6.4.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the US

6.4.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US

6.4.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US

6.5. EU5

6.5.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in EU-5

6.5.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in EU-5

6.5.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in EU-5

6.5.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Germany

6.6. Japan

6.6.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in Japan

6.6.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Japan

6.6.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan

6.6.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan

7. Treatment and Management

7.1. Sequential Approach to Treatment Options for wAIHA and common dosing regimens

7.1.1. First-line therapy

7.1.1.1. Corticosteroids

7.1.2. Second-line therapy

7.1.2.1. Rituximab

7.1.3. Third-line therapy

7.1.3.1. Splenectomy

7.1.3.2. Immunosuppressive drugs

7.1.3.3. Other Options

7.1.4. Rescue Therapy for Emergency Situations

7.2. British Guidelines for wAIHA treatment

8. Organizations contributing toward WAIHA

9. Case Report

10. Patient Journey

11. Emerging Therapies

11.1. Fostamatinib: Rigel Pharmaceuticals

11.1.1. Drug Description

11.1.2. Product Development

11.1.3. Clinical Development

11.1.3.1. Clinical Trials Information

11.1.4. Safety and Efficacy

11.1.5. Product Profile

11.2. APL-2: Apellis Pharmaceuticals, Inc.

11.2.1. Drug Description

11.2.2. Regulatory Milestone

11.2.3. Product Development

11.2.4. Clinical Development

11.2.4.1. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. M281: Johnson & Johnson

11.3.1. Drug Description

11.3.2. Product Development

11.3.3. Clinical Development

11.3.3.1. Clinical Trials Information

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. BIVV009 (Sutimlimab): Sanofi

11.4.1. Drug Description

11.4.2. Product Development

11.4.3. Clinical Development

11.4.3.1. Clinical Trials Information

11.4.4. Safety and Efficacy

11.4.5. Product Profile

11.5. Parsaclisib: Incyte Corporation

11.5.1. Drug Description

11.5.2. Clinical Development

11.5.2.1. Clinical Trials Information

11.5.3. Safety and Efficacy

11.5.4. Product Profile

11.6. Rilzabrutinib: Sanofi

11.6.1. Drug Description

11.6.2. Product Development

11.6.3. Clinical Development

11.6.3.1. Clinical Trials Information

11.6.4. Product Profile

11.7. Isatuximab: Sanofi

11.7.1. Drug Description

11.7.2. Product Development

11.7.3. Clinical Development

11.7.3.1. Clinical Trials Information

11.7.4. Product Profile

11.8. ANX005: Annexon

11.8.1. Drug Description

11.8.2. Clinical Development

11.8.2.1. Clinical Trials Information

11.8.3. Product Profile

12. Warm Autoimmune Hemolytic Anemia: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Warm Autoimmune Hemolytic Anemia in the 7MM

12.3. Market Size by Therapies in the 7MM

13. Country-wise Market Analysis

13.1. Market Outlook

13.2. United States Market Size

13.2.1. Total Market Size of Warm Autoimmune Hemolytic Anemia in the US

13.2.2. Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in the US

13.3. EU-5

13.3.1. Total Market size of Warm Autoimmune Hemolytic Anemia in EU-5

13.3.2. Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in EU-5

13.4. Japan

13.4.1. Total Market size of Warm Autoimmune Hemolytic Anemia in Japan

13.4.2. Market Size of Warm Autoimmune Hemolytic Anemia by Therapies in Japan

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Warm Autoimmune Hemolytic Anemia, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Prevalent Patient Population of wAIHA in the 7MM (2019–2032)

Table 3: Total Prevalent Cases of Warm Autoimmune Hemolytic Anemia in the US (2019–2032)

Table 4: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2019–2032)

Table 5: Type-specific Cases of Warm Autoimmune Hemolytic Anemia in the US (2019–2032)

Table 6: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2019–2032)

Table 7: Total Prevalent Cases of Autoimmune Hemolytic Anemia in EU-5 (2019–2032)

Table 8: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in EU-5 (2019–2032)

Table 9: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in EU-5 (2019–2032)

Table 10: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in EU-5 (2019–2032)

Table 11: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Japan (2019–2032)

Table 12: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2019–2032)

Table 13: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2019–2032)

Table 14: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2019–2032)

Table 15: Treatment Flow

Table 16: Organizations contributing toward wAIHA

Table 17: Fostamatinib, Clinical Trial Description, 2022

Table 18: APL-2, Clinical Trial Description, 2022

Table 19: M281, Clinical Trial Description, 2022

Table 22: BIVV009, Clinical Trial Description, 2022

Table 23: Parsaclisib, Clinical Trial Description, 2022

Table 24: Rilzabrutinib, Clinical Trial Description, 2022

Table 25: Isatuximab, Clinical Trial Description, 2022

Table 26: ANX005 Clinical Trial Description, 2022

Table 27: 7 Major Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2019–2032)

Table 28: 7MM Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2019–2032)

Table 29: The US Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2019–2032)

Table 30: The US Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2019–2032)

Table 31: EU-5Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2019–2032)

Table 32: EU-5Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2019–2032)

Table 33: Japan Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2019–2032)

Table 34: Japan Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2019–2032)

List of Figures

Figure 1: Classification of wAIHA

Figure 2: Mechanisms of Hemolysis IN Warm Antibody Autoimmune Hemolytic Anemia

Figure 3: Mechanisms of Hemolysis in Warm Antibody Autoimmune Hemolytic Anemia

Figure 4: Direct Antiglobulin Test

Figure 5: Total Prevalent Patient Population of wAIHA in the 7MM (2019–2032)

Figure 6: Total Prevalent Cases of AIHA in the US (2019–2032)

Figure 7: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2019–2032)

Figure 8: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2019–2032)

Figure 9: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2019–2032)

Figure 10: Total Prevalent Cases of Autoimmune Hemolytic Anemia in EU-5 (2019–2032)

Figure 11: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in EU-5 (2019–2032)

Figure 12: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in EU-5 (2019–2032)

Figure 13: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in EU-5 (2019–2032)

Figure 14: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Japan (2019–2032)

Figure 15: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2019–2032)

Figure 16: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2019–2032)

Figure 17: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2019–2032)

Figure 18: Treatment algorithm for warm AIHA in adults

Figure 19: 7 Major Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2019–2032)

Figure 20: Market Size by Therapies in USD Million (2019–2032)

Figure 21: The US Market Size of Warm Autoimmune Hemolytic Anemia, USD Million (2019–2032)

Figure 22: The US Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2019–2032)

Figure 23: EU-5Market Size of Warm Autoimmune Hemolytic Anemia, USD Million (2019–2032)

Figure 24: EU-5Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2019–2032)

Figure 25: Japan Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2019–2032)

Figure 26: Japan Market Size of Warm Autoimmune Hemolytic Anemia by Therapies in USD Million (2019–2032)

Rigel Pharmaceuticals
Apellis Pharmaceuticals, Inc.
Johnson & Johnson
Sanofi
Incyte Corporation
Annexon

 

 

Forward to Friend

Need A Quote